4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Short Interest Update

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) was the target of a large increase in short interest during the month of November. As of November 30th, there was short interest totalling 8,520,000 shares, an increase of 8.8% from the November 15th total of 7,830,000 shares. Based on an average daily volume of 894,400 shares, the short-interest ratio is presently 9.5 days.

Institutional Investors Weigh In On 4D Molecular Therapeutics

A number of large investors have recently bought and sold shares of the stock. nVerses Capital LLC acquired a new position in shares of 4D Molecular Therapeutics during the third quarter valued at about $40,000. Values First Advisors Inc. acquired a new position in shares of 4D Molecular Therapeutics during the third quarter valued at about $57,000. Quest Partners LLC grew its holdings in shares of 4D Molecular Therapeutics by 17,409.1% during the second quarter. Quest Partners LLC now owns 5,778 shares of the company’s stock valued at $121,000 after buying an additional 5,745 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in shares of 4D Molecular Therapeutics by 64.6% during the third quarter. China Universal Asset Management Co. Ltd. now owns 9,995 shares of the company’s stock valued at $108,000 after buying an additional 3,922 shares during the last quarter. Finally, Proficio Capital Partners LLC acquired a new position in shares of 4D Molecular Therapeutics during the third quarter valued at about $108,000. 99.27% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

FDMT has been the subject of several research reports. Chardan Capital reissued a “buy” rating and issued a $39.00 price objective on shares of 4D Molecular Therapeutics in a research note on Thursday, November 14th. Morgan Stanley initiated coverage on shares of 4D Molecular Therapeutics in a research note on Thursday, November 21st. They issued an “underweight” rating and a $8.00 price objective for the company. Leerink Partners reissued an “outperform” rating and issued a $36.00 price objective (down previously from $40.00) on shares of 4D Molecular Therapeutics in a research note on Thursday, September 19th. Cantor Fitzgerald downgraded shares of 4D Molecular Therapeutics from an “overweight” rating to a “neutral” rating in a research note on Monday, September 23rd. Finally, HC Wainwright reaffirmed a “buy” rating and set a $36.00 price target on shares of 4D Molecular Therapeutics in a research note on Thursday, November 14th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $42.13.

4D Molecular Therapeutics Stock Down 1.5 %

NASDAQ:FDMT traded down $0.10 during trading hours on Tuesday, reaching $6.38. The company had a trading volume of 169,420 shares, compared to its average volume of 882,602. The firm has a market cap of $294.93 million, a price-to-earnings ratio of -2.24 and a beta of 2.74. The business’s 50-day simple moving average is $8.03 and its two-hundred day simple moving average is $14.34. 4D Molecular Therapeutics has a twelve month low of $6.31 and a twelve month high of $36.25.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.